Buscar
Congreso SOLACI

Búsqueda de: xience

Si no está conforme con los resultados, inténtelo de nuevamente.
Coronary disease

Diffuse Coronary Artery Disease: One-Year 48mm XIENCE Skypoint Outcomes

Long 48mm Stent XIENCE Skypoint in the treatment of diffuse CAD Long coronary artery lesions often involve complex...
solaci -
Ir
Antiplatelet

XIENCE SHORT DAPT | Ideal DAPT Period for Patients at High Risk of Bleeding

In patients at high risk of bleeding undergoing coronary stenting with a Xience stent, 1-to-3-month DAPT period...
solaci -
Ir
Coronary disease

EuroPCR 2021 | CASTLE: Orsiro vs Xience Guided by Intravascular Imaging

According to the CASTLE trial, the Orsino stent—a biodegradable, ultrathin, sirolimus-eluting stent—provides the same results at 12 months...
solaci -
Ir
Antiplatelet

Xience Receives CE Mark for Short and Ultrashort DAPT Schemes

Dual antiplatelet therapy (DAPT) one month after angioplasty with Xience stent was approved in Europe for patients...
solaci -
Ir
Antiplatelet

TCT 2020 | Xience in Favor of Short Dual Antiaggregation Therapy with High Bleeding Risk

Following with aspirin alone after a short period of dual antiaggregation therapy (DAPT), 1 to 3 months,...
solaci -
Ir
Coronary disease

Theoretical Advantages Translated into Worst Clinical Outcomes: Synergy vs. Xience

New data from a real-world registry soon to be published in J Am Coll Cardiol Intv suggest...
solaci -
Ir
Coronary disease

EuroPCR 2019 | Stent Firehawk Continues to Show Good Results at 2 Years vs. Xience

This device, an abluminal groove-filled biodegradable-polymer sirolimus-eluting stent manufactured in China, showed very similar efficacy and safety...
solaci -
Ir
Coronary disease

DESSOLVE III: Xience vs. MiStent

The MiStent device is made of cobalt-chromium, with struts of up to 64 µm thick. It is coated...
solaci -
Ir

SOLACI es la organización de referencia del intervencionismo cardiovascular latinoamericano.

Últimas Noticias

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

Dr. Omar Tupayachi - 0
While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Dr. Andrés Rodríguez - 0
Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Dr. Omar Tupayachi - 0
Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....

Noticias Institucionales

Check out the best images of the El Salvador 2024 Sessions

solaci - 0
Review the highlights of the XLIX SOLACI Regional Sessions held at the Intercontinental Hotel in San Salvador, El Salvador between November 7 and 8,...

The El Salvador 2024 Sessions are coming soon

solaci - 0
The XLIX SOLACI 2024 Regional Sessions (17th Central America & the Caribbean) are approaching, and will take place in the city of San Salvador (El Salvador)....

Check out the best images of the Arequipa 2024 Sessions

solaci - 0
Review the highlights of the XVIII SOLACI Regional Sessions held at the Hanan Hotel in Arequipa, Peru between October 3 and 4, 2024. <!-- wp:tw/bwg...

Accesos

Adolfo Alsina 2653 · Piso 2H · CABA · Buenos Aires · Argentina · (5411) 4954 7173 · info@solaci.org · solaci.org · Términos de uso -Políticas de privacidad